May 29 |
Equillium to Present at the Jefferies Global Healthcare Conference
|
May 14 |
Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
|
May 9 |
Equillium GAAP EPS of -$0.08, revenue of $10.7M
|
May 9 |
Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates
|
May 9 |
Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights
|
May 7 |
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
|
May 2 |
We're Keeping An Eye On Equillium's (NASDAQ:EQ) Cash Burn Rate
|
Apr 3 |
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
Apr 1 |
5 Stocks That More Than Doubled in Q1 With More Gains Ahead
|
Apr 1 |
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis
|